International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Global Antihyperlipidemic Drugs Market Research Report 2023-2028:
According to the latest report by IMARC Group, titled " Antihyperlipidemic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Fo recast 2023-2028
," the global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022.
Antihyperlipidemic drugs help in lowering blood lipid levels, including cholesterol. These medications are also known as hypolipidemic or lipid-lowering drugs in reference to their main physiological effects. They can be taken along with different medicines to lower cholesterol and reduce the risk of developing certain diseases. Some commonly available antihyperlipidemic drugs include cholesterol absorption inhibitors, fibric acid derivatives, statins, antihyperlipidemic combinations, bile acid sequestrants, and PCSK9 inhibitors. These drugs can prevent absorption, facilitate the elimination of more lipids in feces, and increase good cholesterol levels to lower bad cholesterol. At present, antihyperlipidemic drugs are available in different classes across the globe, which can be given depending on the patient’s underlying disease, cholesterol profile, and other factors.
Request for a PDF sample of this report:
https://www.imarcgroup.com/antihyperlipidemic-drugs-market/requestsample
The rising prevalence of hyperlipidemia due to the high consumption of fatty foods and nicotine addiction represents the primary factor driving the market growth. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is a leading cause of death among adults. In line with this, the escalating demand for antihyperlipidemic drugs to improve the low levels of highdensity lipoprotein (HDL) cholesterol while reducing the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides are positively influencing the market growth. Additionally, antihyperlipidemic drugs are used to treat high cholesterol levels and various lipid disorders in children. Along with this, the rising product demand to reduce hospitalization rates and premature deaths due to the increase in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population has catalyzed market growth. Furthermore, several key players are developing, synthesizing, and evaluating a variety of new molecules for these drugs, thereby contributing to market growth. Other factors, including the rising prevalence of sedentary lifestyles, increasing incidences of cardiovascular disorders, surging approval of new and advanced drugs, and expanding geriatric population, are also anticipated to create a positive market outlook.
Looking forward, IMARC Group expects the market value to reach US$ 16.0 Billion by 2028, expanding at a CAGR of 4.6% during 2023-2028.
View Report TOC, Figures and Tables: https://www.imarcgroup.com/antihyperlipidemic-drugs-market
Key Market Segmentation
The research report includes the following segments:
Breakup by Drug Class:
• Statins
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• PCSK9 Inhibitors
• Combination
• Others
Breakup by Route of Administration:
• Oral
• Intravenous
Breakup by Distribution Channel:
• Hospital Pharmacies
• Retail Stores
• Online Retailers
Breakup by Region:
• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa
Competitive Landscape with Key Players:
• Amgen Inc
• AstraZeneca plc
• Daiichi Sankyo Company Limited
• Merck & Co. Inc
• Novartis AG
• Pfizer Inc
• Sanofi S.A
1. What was the size of the global antihyperlipidemic drugs market in 2022?
2. What is the expected growth rate of the global antihyperlipidemic drugs market during 20232028?
3. What are the key factors driving the global antihyperlipidemic drugs market?
4. What has been the impact of COVID-19 on the global antihyperlipidemic drugs market?
5. What is the breakup of the global antihyperlipidemic drugs market based on the drug class?
6. What is the breakup of the global antihyperlipidemic drugs market based on the distribution channel?
7. What are the key regions in the global antihyperlipidemic drugs market?
8. Who are the key players/companies in the global antihyperlipidemic drugs market?
Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/antihyperlipidemic-drugs-market/toc
We are the trusted business partners to the world's leading corporates, governments, and institutions
We are the trusted business partners to the world's leading corporates, governments, and institutions
© 2022 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
